This chapter deals with the indications, contraindications and complications of blood transfusion in the ICU. The contents and properties of packed red blood cells, the physiology of acute haemorrhage and the physiological responses to blood transfusion are detailed in other chapters.
The National Blood Authority of Australia has issued a series of practice guidelines which can be helpful in guiding the shaking bloodied hand of the ICU practitoner. The guidelines have been endorsed by our college, which means that at least some of the Australian intensivists must agree with them.
The following entries are a summary of these clinical practice guidelines, to help answer past paper SAQs such as Question 21 from the second paper of 2007 and Question 13 from the first paper of 2003.
The critical care module of the NBA guidelines makes the following recommendations for critically ill patients who are not hosing blood out of every orifice:
The NBA makes the following statements about the use of separated blood products:
Much of the above has been guided by the 1999 TRICC study, which observed the effects of transfusing 838 ICU patients to different Hb levels (70-90 vs 100-120). Though they did not find any 30-day mortality difference between the two groups, there was a significant in-hospital mortality difference (22% vs 28%) which favoured the restrictive transfusion strategy.
Since 1999, many more RCTs have contributed data to the growing impression that keeping Hb over 70 in most patients is a superior approach in terms of mortality and morbidity. A 2013 JAMA article provides a helpful synopsis of these results, and summarizes a total of over 6000 patient cases in support of restrictive transfusion practice. The lower haemoglobin threshold was associated with no harm, and may be associated with some sort of survival benefit.
A "routine transfusion" in this setting is the transfusion which has a "numeric trigger" as opposed to a clinical indication (i.e. the patient is asymptomatic).
Spahn et al (2013) have done an excellent review of this for Lancet. In summary:
Goodnough, Lawrence T., Jerrold H. Levy, and Michael F. Murphy. "Concepts of blood transfusion in adults." The Lancet 381.9880 (2013): 1845-1854.
Spahn, Donat R., and Lawrence T. Goodnough. "Alternatives to blood transfusion." The Lancet 381.9880 (2013): 1855-1865.
There is also a rescinded document from the NHMRC (2001) which has been used to guide practice: Clinical Practice Guidelines on the Use of Blood Components.
To some extent this document has been superceded by the Australian and New Zealand Society of Blood Transfusion GUIDELINES FOR THE ADMINISTRATION OF BLOOD PRODUCTS.
The Patient Blood Management Guidelines from the National Blood Authority of Australia is another series of documents worth looking at - it contains several important modules which have been reviewed and which act as successors to the 2001 NHMRC guidelines.
Treleaven, Jennie, et al. "Guidelines on the use of irradiated blood components prepared by the British Committee for Standards in Haematology blood transfusion task force." British Journal of Haematology 152.1 (2011): 35-51.
Aoun, Elie, et al. "Transfusion‐associated GVHD: 10 years’ experience at the American University of Beirut—Medical Center." Transfusion 43.12 (2003): 1672-1676.
Heddle, Nancy M., and Morris A. Blajchman. "The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions [editorial]." Blood 85.3 (1995): 603-606.
Sharma, R. R., and Neelam Marwaha. "Leukoreduced blood components: Advantages and strategies for its implementation in developing countries."Asian journal of transfusion science 4.1 (2010): 3.
Dzik, Walter H. "Leukoreduction of blood components." Current opinion in hematology 9.6 (2002): 521-526.
Corwin, Howard L., and James P. AuBuchon. "Is leukoreduction of blood components for everyone?." JAMA 289.15 (2003): 1993-1995.
Blajchman, M. A. "The clinical benefits of the leukoreduction of blood products."Journal of Trauma-Injury, Infection, and Critical Care 60.6 (2006): S83-S90.
Rosenbaum, Lizabeth, et al. "The reintroduction of nonleukoreduced blood: would patients and clinicians agree?." Transfusion 51.12 (2011): 2739-2743.
Bilgin, Y. M., L. M. van de Watering, and A. Brand. "Clinical effects of leucoreduction of blood transfusions." Neth J Med 69.10 (2011): 441-450.
Australian Red Cross - Blood Service Policy on "The Age of Red Cells"
Hess, John R. "Red cell changes during storage." Transfusion and Apheresis Science 43.1 (2010): 51-59.
Bennett-Guerrero, Elliott, et al. "Evolution of adverse changes in stored RBCs."Proceedings of the National Academy of Sciences 104.43 (2007): 17063-17068.
Hébert, Paul C., et al. "A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care." New England Journal of Medicine340.6 (1999): 409-417.
Carson, Jeffrey L., Paul A. Carless, and Paul C. Hébert. "Outcomes using lower vs higher hemoglobin thresholds for red blood cell transfusion." Jama 309.1 (2013): 83-84.
Lelubre, C., J. L. Vincent, and F. S. Taccone. "Red blood cell transfusion strategies in critically ill patients: lessons from recent randomized clinical studies." Minerva anestesiologica (2016).
Spahn, Donat R., and Lawrence T. Goodnough. "Alternatives to blood transfusion." The Lancet 381.9880 (2013): 1855-1865.
Roberts, Ian, et al. "Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial." The Lancet 395.10241 (2020): 1927-1936.